BMY Stock Analysis
💡 Quick Answer
Across 4 APEX technical signals, BMY is currently split between bullish and bearish readings — 0 bullish, 0 bearish as of 2026-06-11. Run a live analysis to see the current composite score.
BMY is primarily a value and dividend trade rather than a momentum name, with low ATR (1.5-2%) and a 5%+ dividend yield. It is sensitive to pipeline news and FDA approval decisions.
Bristol-Myers Squibb is a global biopharmaceutical company with leading oncology (Opdivo, Revlimid) and cardiovascular (Eliquis) franchises. The company faces a patent cliff on Eliquis through 2026-2028, requiring its pipeline and recent acquisitions (Karuna Therapeutics, RayzeBio) to offset loss-of-exclusivity revenue. Despite the patent headwind, BMY's 5%+ dividend yield and sub-10x earnings multiple make it a value and income play.
Why Do Traders Watch BMY?
BMY is primarily a value and dividend trade rather than a momentum name, with low ATR (1.5-2%) and a 5%+ dividend yield. It is sensitive to pipeline news and FDA approval decisions. Post-earnings moves of 3-5% are typical. The stock attracts contrarian buyers when its yield rises above 5.5%. A level that has historically triggered institutional accumulation from income funds seeking healthcare exposure.
Is BMY a Buy Right Now? Current Signal Readings
BMY's elevated dividend yield creates a durable institutional demand floor. When the yield rises above 5.5% due to price weakness. Without a dividend cut signal. Income-oriented funds historically accumulate shares within 2-3 weeks. Monitoring payout ratio and free cash flow coverage confirms sustainability.
BMY's FDA approval decisions on pipeline drugs (particularly in oncology and immunology) create binary catalyst events with 5-15% stock moves. The PDUFA (FDA action) dates are publicly known months in advance. Position sizing before these dates requires accounting for both approval and rejection scenarios.
BMY's RSI oscillates in a lower range than growth peers, reflecting its value stock characteristics. RSI at 35-38 with the dividend yield above 5.5% has historically been the highest-conviction BMY entry. Value investors and income funds converge at this level creating reliable demand.
Eliquis (apixaban) patent expiry and generic competition is the primary fundamental risk for BMY through 2028. Each pipeline drug that demonstrates clinical success. Replacing Eliquis revenue. Reduces this overhang. Track NEJM publications and conference presentations for pivotal trial data as early signals of pipeline success.
📋 BMY Key Stats for Traders
APEX combines RSI, MACD, Fibonacci, Volume, and 4 more signals into one composite score in under 30 seconds.
Analyze BMY Free →